Next Article in Journal
Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells
Previous Article in Journal
Chemical Diversity, Biological Activity, and Genetic Aspects of Three Ocotea Species from the Amazon

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan
Diabetic Neuropathy Project, Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan
Author to whom correspondence should be addressed.
Academic Editor: Joseph V. Moxon
Int. J. Mol. Sci. 2017, 18(5), 1083;
Received: 30 January 2017 / Revised: 3 May 2017 / Accepted: 15 May 2017 / Published: 18 May 2017
(This article belongs to the Section Biochemistry)
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium–glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering agent suggested to exert renoprotective effects in glucose lowering-dependent and independent fashions. Experimental studies have shown that SGLT2 inhibitors attenuate DN in animal models of both type 1 diabetes (T1D) and type 2 diabetes (T2D), indicating a potential renoprotective effect beyond glucose reduction. Renoprotection by SGLT2 inhibitors has been demonstrated in T2D patients with a high cardiovascular risk in randomized controlled trials (RCTs). These favorable effects of SGLT2 inhibitors are explained by several potential mechanisms, including the attenuation of glomerular hyperfiltration, inflammation and oxidative stress. In this review article, we discuss the renoprotective effects of SGLT2 inhibitors by integrating experimental findings with the available clinical data. View Full-Text
Keywords: diabetic nephropathy; cardiovascular disease; SGLT2 inhibitors diabetic nephropathy; cardiovascular disease; SGLT2 inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Kawanami, D.; Matoba, K.; Takeda, Y.; Nagai, Y.; Akamine, T.; Yokota, T.; Sango, K.; Utsunomiya, K. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. Int. J. Mol. Sci. 2017, 18, 1083.

AMA Style

Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, Sango K, Utsunomiya K. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. International Journal of Molecular Sciences. 2017; 18(5):1083.

Chicago/Turabian Style

Kawanami, Daiji, Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, Tomoyo Akamine, Tamotsu Yokota, Kazunori Sango, and Kazunori Utsunomiya. 2017. "SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy" International Journal of Molecular Sciences 18, no. 5: 1083.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop